1. Scrip
  2. >>Archive

Astex Technology Ltd.

 
• By Mary Stuart

The focus of Astex Technology Ltd., which aims to imrpove the efficiency of protein X-ray crystallography, reflects the drug development background of its founders. X-ray crystallography can be used as a target validation tool, and also in drug discovery, to optimize ligand-protein interactions. Astex will first aim to introduce tools for the latter market.

The focus of start-up Astex Technology Ltd. , which aims to improve the efficiency of protein X-ray crystallography, reflects the practical experience of its founders in trying to accelerate the development of pharmaceutical compounds. For eight years, Astex co-founder Harren Jhoti, PhD was head of Structural Biology at Glaxo Wellcome PLC as well as head of UK bioinformatics. He perceives two large potential markets for the Astex technology. X-ray crystallography can be used as a target-discovery tool, and, also in drug discovery, to optimize ligand-protein interactions. Astex will introduce tools for the latter market, because "the technology is most needed where the compounds are," Jhoti says.

The company's goal is to develop methods for high-throughput X-ray crystallography. Academic centers attempting to increase output by dedicating massive...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.